Biovica and the outlook after the CMD: A road map to the US market

Biovica’s CLIA certified San Diego lab, together with the summer of 2022 FDA 510 (k) approval is the backbone of Biovica’s strategy to reach most of the US market.

Länk till analysen i sin helhet: https://www.redeye.se/research/842613/biovica-and-the-outlook-after-the-cmd-a-road-map-to-the-us-market?utm_source=finwire&utm_medium=RSS